다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Molecular psychiatry, v.6 no.2, 2001년, pp.230 - 234
Basile, V S (Neurogenetics Section, Clarke Institute of Psychiatry, Centre for Addiction and Mental Health (CAMH), University of Toronto, Toronto, Canada) , Ozdemir, V (Neurogenetics Section, Clarke Institute of Psychiatry, Centre for Addiction and Mental Health (CAMH), University of Toronto, Toronto, Canada, and Department of Pharmacology, University of Toronto, Toronto, Canada) , Masellis, M (Neurogenetics Section, Clarke Institute of Psychiatry, Centre for Addiction and Mental Health (CAMH), University of Toronto, Toronto, Canada) , Meltzer, H Y (Department of Psychiatry, Vanderbilt University, Nashville, USA) , Lieberman, J A (Department of Psychiatry, University of North Carolina, Chapel Hill, USA) , Potkin, S G (Department of Psychiatry, University of California, Irvine, USA) , Macciardi, F M (Neurogenetics Section, Clarke Institute of Psychiatry, Centre for Addiction and Mental Health (CAMH), University of Toronto, Toronto, Canada) , Petronis, A (Neurogenetics Section, Clarke Institute of Psychiatry, Centre for Addiction and Mental Health (CAMH), University of Toronto, Toronto, Canada) , Kennedy, J L (Neurog)
AI-Helper
Tardive dyskinesia (TD) is a disabling neurological side effect associated with long-term treatment with typical antipsychotics. Family studies and animal models lend evidence for hereditary predisposition to TD. The newer atypical antipsychotics pose a minimal risk for TD which is in part attribute...
J Clin Psychiatry GM Simpson 61 39 2000 10.4088/JCP.v61n0110 Simpson GM . The treatment of tardive dyskinesia and tardive dystonia J Clin Psychiatry 2000 61: (Suppl 4) 39-44
Biol Psychiatry J Bergen 32 580 1992 10.1016/0006-3223(92)90071-7 Bergen J, Kitchin R, Berry G . Predictors of the course of tardive dyskinesia in patients receiving neuroleptics Biol Psychiatry 1992 32: 580-594
J Clin Psychiatry P Weinhold 42 165 1981 Weinhold P, Wegner JT, Kane JM . Familial occurrence of tardive dyskinesia J Clin Psychiatry 1981 42: 165-166
Am J Psychiatry R Yassa 138 1618 1981 10.1176/ajp.138.12.1618 Yassa R, Ananth J . Familial tardive dyskinesia Am J Psychiatry 1981 138: 1618-1619
Br J Psychiatry JL Waddington 153 376 1988 10.1192/bjp.153.3.376 Waddington JL, Youssef HA . The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree Br J Psychiatry 1988 153: 376-381
Pharmacol Biochem Behav H Rosengarten 49 663 1994 10.1016/0091-3057(94)90085-X Rosengarten H, Schweitzer JW, Friedhoff AJ . Possible genetic factors underlying the pathophysiology of tardive dyskinesia Pharmacol Biochem Behav 1994 49: 663-667
Mol Psychiatry VS Basile 5 410 2000 10.1038/sj.mp.4000736 Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia Mol Psychiatry 2000 5: 410-417
Neuropsychopharmacology H Hori 23 170 2000 10.1016/S0893-133X(99)00156-6 Hori H, Ohmori O, Shinkai T, Kojima H, Okano C, Suzuki T et al. Manganese superoxide dismutase gene polymorphism and schizophrenia. Relation to tardive dyskinesia Neuropsychopharmacology 2000 23: 170-177
Basile VS, Masellis M, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL . Application of pharmacogenetics of schizophrenia: emerging insights from studies of clozapine response and tardive dyskinesia In: Brier A, Tran PV, Herrera J, Bymaster F, Tollefson G (eds). Current Issues in the Psychopharmacology of Schizophrenia Lippincott Williams & Wilkins, New York 2000 (in press
Neuropsychopharmacology VS Basile 21 17 1999 10.1016/S0893-133X(98)00114-6 Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA et al. Association of the Mscl polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia Neuropsychopharmacology 1999 21: 17-27
Mol Psychiatry R Segman 4 247 1999 10.1038/sj.mp.4000511 Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia Mol Psychiatry 1999 4: 247-253
Mol Psychiatry VM Steen 2 139 1997 10.1038/sj.mp.4000249 Steen VM, Lovlie R, MacEwan T, McCreadie RG . Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients Mol Psychiatry 1997 2: 139-145
Br J Psychiatry M Armstrong 170 23 1997 10.1192/bjp.170.1.23 Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR . Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype Br J Psychiatry 1997 170: 23-26
Neuropsychopharmacology HY Meltzer 21 106S 1999 10.1016/S0893-133X(99)00046-9 Meltzer HY . The role of serotonin in antipsychotic drug action Neuropsychopharmacology 1999 21: 106S-115S
Nature S Nedergaard 333 174 1988 10.1038/333174a0 Nedergaard S, Bolam JP, Greenfield SA . Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra Nature 1988 333: 174-177
Crit Rev Neurobiol BL Roth 12 319 1998 10.1615/CritRevNeurobiol.v12.i4.30 Roth BL, Berry SA, Kroeze WK, Willins DL, Kristiansen K . Serotonin 5-HT2A receptors: molecular biology and mechanisms of regulation Crit Rev Neurobiol 1998 12: 319-338
J Pharmacol Exp Ther HY Meltzer 251 238 1989 Meltzer HY, Matsubara S, Lee JC . Classification of typical and atypical antipsychotic drugs on the basis of dopamine-D-1, -D-2, and serotonin-2 pKi values J Pharmacol Exp Ther 1989 251: 238-246
Arch Gen Psychiatry NR Schooler 39 486 1982 Schooler NR, Kane JM . Research diagnoses for tardive dyskinesia Arch Gen Psychiatry 1982 39: 486-487
Neuropsychopharmacology M Masellis 19 123 1998 10.1016/S0893-133X(98)00007-4 Masellis M, Basile VS, Meltzer HY et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients Neuropsychopharmacology 1998 19: 123-132
Science ES Lander 265 2037 1994 10.1126/science.8091226 Lander ES, Schork NJ . Genetic dissection of complex traits Science 1994 265: 2037-2048
Aberrant sequence or regulation? Neuropsychopharmacology A Petronis 23 1 2000 10.1016/S0893-133X(00)00127-5 Petronis A . The genes for major psychosis Aberrant sequence or regulation? Neuropsychopharmacology 2000 23: 1-12
Nucleic Acids Res DK Lahiri 19 5444 1991 10.1093/nar/19.19.5444 Lahiri DK, Nurnberger JI Jr . A rapid nonenzymatic method for the preparation of HMW DNA from blood for RFLP studies Nucleic Acids Res 1991 19: 5444
Hum Mol Genet JT Warren 2 338 1993 10.1093/hmg/2.3.338 Warren JT, Jr, Peacock ML, Rodriguez LC, Fink JK . An Mspl polymorphism in the human serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis Hum Mol Genet 1993 2: 338
J Neurochem N Ozaki 68 2186 1997 10.1046/j.1471-4159.1997.68052186.x Ozaki N, Manji H, Lubierman V, Lu SJ, Lappalainen J, Rosenthal NE et al. A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization J Neurochem 1997 68: 2186-2193
Lancet MM Nothen 346 908 1995 10.1016/S0140-6736(95)92756-5 Nothen MM, Rietschel M, Erdmann J, Oberlander H, Moller HJ, Naber D et al. Genetic variation of the 5-HT2A receptor and response to clozapine Lancet 1995 346: 908-909
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.